{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:41:19Z","timestamp":1792078879808,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jagp.2021.01.015","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T09:52:35Z","timestamp":1611741155000},"page":"1253-1263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Cannabinoids for Agitation in Alzheimer's Disease"],"prefix":"10.1016","volume":"29","author":[{"given":"John D.","family":"Outen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Haroon","family":"Burhanullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Vandrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regan E.","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose L.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Agronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent P.","family":"Forester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jagp.2021.01.015_bib0001","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/NDT.S3016","article-title":"An update on the toxicity of Abeta in Alzheimer's disease","volume":"4","author":"Gotz","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jagp.2021.01.015_bib0002","series-title":"Facts and Figures","year":"2020"},{"key":"10.1016\/j.jagp.2021.01.015_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fnagi.2019.00074","article-title":"Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease","volume":"11","author":"Younes","year":"2019","journal-title":"Front Aging Neurosci"},{"issue":"5054","key":"10.1016\/j.jagp.2021.01.015_bib0004","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jagp.2021.01.015_bib0005","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0166-2236(93)90078-Z","article-title":"Tau protein and the neurofibrillary pathology of Alzheimer's disease","volume":"16","author":"Goedert","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jagp.2021.01.015_bib0006","series-title":"Medications for Memory","year":"2020"},{"issue":"6","key":"10.1016\/j.jagp.2021.01.015_bib0007","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40264-014-0161-z","article-title":"Cardiovascular effects of drugs used to treat Alzheimer's disease","volume":"37","author":"Howes","year":"2014","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.jagp.2021.01.015_bib0008","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1532-5415.2011.03450.x","article-title":"Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials","volume":"59","author":"Kim","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.jagp.2021.01.015_bib0009","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/gps.1858","article-title":"Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study","volume":"23","author":"Steinberg","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"11","key":"10.1016\/j.jagp.2021.01.015_bib0010","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/JGP.0b013e3181d6b68d","article-title":"Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease","volume":"18","author":"Spalletta","year":"2010","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.jagp.2021.01.015_bib0011","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jamda.2014.12.018","article-title":"The course of neuropsychiatric symptoms in dementia: a 3-year longitudinal study","volume":"16","author":"Brodaty","year":"2015","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"10.1016\/j.jagp.2021.01.015_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007382","article-title":"Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study","volume":"5","author":"Morris","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.jagp.2021.01.015_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mam.2015.05.005","article-title":"Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?","volume":"43-44","author":"Rosenberg","year":"2015","journal-title":"Mol Aspects Med"},{"issue":"Pt 9","key":"10.1016\/j.jagp.2021.01.015_bib0015","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/brain\/awn151","article-title":"Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease","volume":"131","author":"Bruen","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3233\/JAD-2010-1223","article-title":"Grey and white matter changes at different stages of Alzheimer's disease","volume":"19","author":"Serra","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.jagp.2021.01.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137121","article-title":"Posterior Atrophy and Medial Temporal Atrophy Scores Are Associated with Different Symptoms in Patients with Alzheimer's Disease and Mild Cognitive Impairment","volume":"10","author":"Hsu","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jagp.2021.01.015_bib0018","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1176\/appi.neuropsych.11120375","article-title":"Diffusion tensor imaging of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's dementia","volume":"24","author":"Tighe","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"10.1016\/j.jagp.2021.01.015_bib0019","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hbm.22248","article-title":"Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the salience network","volume":"35","author":"Balthazar","year":"2014","journal-title":"Hum Brain Mapp"},{"issue":"5 Suppl","key":"10.1016\/j.jagp.2021.01.015_bib0020","article-title":"Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease","volume":"9","author":"Trzepacz","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.jagp.2021.01.015_bib0021","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.72","article-title":"Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease","volume":"49","author":"Tekin","year":"2001","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.jagp.2021.01.015_bib0022","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/archneur.61.11.1731","article-title":"Medial temporal hypoperfusion and aggression in Alzheimer disease","volume":"61","author":"Lanctot","year":"2004","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.jagp.2021.01.015_bib0023","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archneur.57.6.861","article-title":"Left frontotemporal hypoperfusion is associated with aggression in patients with dementia","volume":"57","author":"Hirono","year":"2000","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0024","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","article-title":"The serotonergic system in ageing and Alzheimer's disease","volume":"99","author":"Rodriguez","year":"2012","journal-title":"Prog Neurobiol"},{"issue":"8","key":"10.1016\/j.jagp.2021.01.015_bib0025","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archneur.61.8.1249","article-title":"Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease","volume":"61","author":"Assal","year":"2004","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.jagp.2021.01.015_bib0026","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archneur.58.9.1425","article-title":"The 5-HTTPR*S\/*L polymorphism and aggressive behavior in Alzheimer disease","volume":"58","author":"Sukonick","year":"2001","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.jagp.2021.01.015_bib0027","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archneur.55.10.1335","article-title":"Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease","volume":"55","author":"Sweet","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jagp.2021.01.015_bib0028","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fnagi.2017.00087","article-title":"Genetics of Aggression in Alzheimer's Disease (AD)","volume":"9","author":"Lukiw","year":"2017","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"10.1016\/j.jagp.2021.01.015_bib0029","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1081\/CBI-100101046","article-title":"Circadian rhythms and sleep in human aging","volume":"17","author":"Van Someren","year":"2000","journal-title":"Chronobiol Int"},{"issue":"5","key":"10.1016\/j.jagp.2021.01.015_bib0030","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1176\/appi.ajp.158.5.704","article-title":"Sundowning and circadian rhythms in Alzheimer's disease","volume":"158","author":"Volicer","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.jagp.2021.01.015_bib0031","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00019442-200505000-00004","article-title":"Disturbance of endogenous circadian rhythm in aging and Alzheimer disease","volume":"13","author":"Harper","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.jagp.2021.01.015_bib0032","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002512-200825050-00003","article-title":"Alternatives to atypical antipsychotics for the management of dementia-related agitation","volume":"25","author":"Passmore","year":"2008","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0033","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13607863.2016.1235680","article-title":"Delirium and mental health history as predictors of aggression in individuals with dementia in inpatient settings","volume":"22","author":"Wharton","year":"2018","journal-title":"Aging Ment Health"},{"issue":"4","key":"10.1016\/j.jagp.2021.01.015_bib0034","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S1041610212002232","article-title":"Relationship between delirium and behavioral symptoms of dementia","volume":"25","author":"Landreville","year":"2013","journal-title":"Int Psychogeriatr"},{"issue":"6","key":"10.1016\/j.jagp.2021.01.015_bib0035","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/gps.2381","article-title":"Association between altered systemic inflammatory interleukin-1beta and natural killer cell activity and subsequently agitation in patients with Alzheimer disease","volume":"25","author":"Higuchi","year":"2010","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.jagp.2021.01.015_bib0036","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jalz.2012.12.001","article-title":"Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future","volume":"9","author":"Geda","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.jagp.2021.01.015_bib0037","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1038\/tp.2017.199","article-title":"Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy","volume":"7","author":"Ijaopo","year":"2017","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0038","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","article-title":"Risk of mortality among individual antipsychotics in patients with dementia","volume":"169","author":"Kales","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"2 and 3-Spec Issue","key":"10.1016\/j.jagp.2021.01.015_bib0039","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","article-title":"The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease","volume":"28","author":"Karl","year":"2017","journal-title":"Behav Pharmacol"},{"issue":"5642","key":"10.1016\/j.jagp.2021.01.015_bib0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jagp.2021.01.015_bib0041","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuint.2011.11.004","article-title":"[(1)(2)(5)I]SD-7015 reveals fine modalities of CB(1) cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease","volume":"60","author":"Farkas","year":"2012","journal-title":"Neurochem Int"},{"issue":"8","key":"10.1016\/j.jagp.2021.01.015_bib0042","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ramirez","year":"2005","journal-title":"J Neurosci"},{"issue":"35","key":"10.1016\/j.jagp.2021.01.015_bib0043","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.jagp.2021.01.015_bib0044","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","article-title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients","volume":"34","author":"Solas","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jagp.2021.01.015_bib0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainres.2009.05.098","article-title":"The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages","volume":"1283","author":"Tolon","year":"2009","journal-title":"Brain Res"},{"issue":"8","key":"10.1016\/j.jagp.2021.01.015_bib0046","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.3390\/ph3082647","article-title":"The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism","volume":"3","author":"Jenny","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.jagp.2021.01.015_bib0047","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/mp060066m","article-title":"A molecular link between the active component of marijuana and Alzheimer's disease pathology","volume":"3","author":"Eubanks","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jagp.2021.01.015_bib0048","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neurobiolaging.2019.03.008","article-title":"Aging circadian rhythms and cannabinoids","volume":"79","author":"Hodges","year":"2019","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jagp.2021.01.015_bib0049","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fphar.2014.00037","article-title":"Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic","volume":"5","author":"Aso","year":"2014","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0050","doi-asserted-by":"crossref","first-page":"e53390","DOI":"10.1371\/journal.pone.0053390","article-title":"Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation","volume":"8","author":"Iring","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jagp.2021.01.015_bib0051","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09540261.2018.1491107","article-title":"The cannabis conundrum: steering policy and medicine with insufficient data","volume":"30","author":"Vandrey","year":"2018","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.jagp.2021.01.015_bib0052","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.arr.2014.01.007","article-title":"Efficacy and safety of medical cannabinoids in older subjects: a systematic review","volume":"14","author":"van den Elsen","year":"2014","journal-title":"Ageing Res Rev"},{"issue":"8","key":"10.1016\/j.jagp.2021.01.015_bib0053","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11910-017-0766-6","article-title":"The Use of Cannabinoids in Treating Dementia","volume":"17","author":"Weier","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.jagp.2021.01.015_bib0054","article-title":"Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis","author":"Bahji","year":"2019","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jagp.2021.01.015_bib0055","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619846993","article-title":"Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review","volume":"10","author":"Hillen","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jagp.2021.01.015_bib0056","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pbb.2019.03.006","article-title":"Cannabinoids, interoception, and anxiety","volume":"180","author":"Andrade","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"10.1016\/j.jagp.2021.01.015_bib0057","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14740\/jocmr4159","article-title":"The Impact of Cannabidiol on Psychiatric and Medical Conditions","volume":"12","author":"Oberbarnscheidt","year":"2020","journal-title":"J Clin Med Res"},{"issue":"16","key":"10.1016\/j.jagp.2021.01.015_bib0058","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","article-title":"Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development","volume":"19","author":"Nguyen","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jagp.2021.01.015_bib0059","series-title":"FDA and Cannabis: Research and Drug Approval Process","year":"2020"},{"issue":"4","key":"10.1016\/j.jagp.2021.01.015_bib0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jagp.2012.11.022","article-title":"Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms","volume":"22","author":"Woodward","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"10.1016\/j.jagp.2021.01.015_bib0061","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3390\/ph3082689","article-title":"Cannabinoids and Dementia: A Review of Clinical and Preclinical Data","volume":"3","author":"Walther","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.jagp.2021.01.015_bib0062","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0063","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/gps.1828","article-title":"The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation","volume":"23","author":"Passmore","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.jagp.2021.01.015_bib0064","first-page":"1","article-title":"Cannabinoids for the treatment of dementia","author":"Krishnan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"3-4","key":"10.1016\/j.jagp.2021.01.015_bib0065","first-page":"142","article-title":"Synthetic Cannabinoids in Dementia with Agitation: Case Studies and Literature Review","volume":"10","author":"Amanullah","year":"2013","journal-title":"Clinical Neuropsychiatry"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0066","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JAD-150915","article-title":"Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study","volume":"51","author":"Shelef","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.jagp.2021.01.015_bib0067","doi-asserted-by":"crossref","first-page":"301","DOI":"10.9758\/cpn.2017.15.4.301","article-title":"A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders","volume":"15","author":"Lim","year":"2017","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"4","key":"10.1016\/j.jagp.2021.01.015_bib0068","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2217\/nmt-2018-0019","article-title":"Cannabinoids for the treatment of behavioral and psychological symptoms of dementia","volume":"8","author":"Tampi","year":"2018","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"10.1016\/j.jagp.2021.01.015_bib0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.18r12617","article-title":"Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis","volume":"80","author":"Ruthirakuhan","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","article-title":"How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review","volume":"269","author":"Hoch","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jagp.2021.01.015_bib0071","series-title":"Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines","author":"Peprah","year":"2019"},{"issue":"1","key":"10.1016\/j.jagp.2021.01.015_bib0072","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000498924","article-title":"Prescription of a THC\/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva","volume":"2","author":"Broers","year":"2019","journal-title":"Medical Cannabis and Cannabinoids"},{"key":"10.1016\/j.jagp.2021.01.015_bib0073","first-page":"1","article-title":"Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials","author":"Charernboon","year":"2020","journal-title":"Clin Gerontol"},{"issue":"3","key":"10.1016\/j.jagp.2021.01.015_bib0074","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1097\/MJT.0000000000001120","article-title":"A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia","volume":"27","author":"Paunescu","year":"2020","journal-title":"Am J Ther"},{"key":"10.1016\/j.jagp.2021.01.015_bib0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fpsyt.2020.00413","article-title":"Cannabinoid as Beneficial Replacement Therapy for Psychotropics to Treat Neuropsychiatric Symptoms in Severe Alzheimer's Dementia: A Clinical Case Report","volume":"11","author":"Defrancesco","year":"2020","journal-title":"Front Psychiatry"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748121000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748121000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:31:57Z","timestamp":1761021117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748121000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1064748121000300"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2021.01.015","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids for Agitation in Alzheimer's Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2021.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}